Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(2006): Fix OK+, Clin Gastroenterol Hepatol 4(4), xxvi
Hot flashes (1–10%)
Hypersensitivity (1–10%)
(2003): Feliciani C+, Int J Immunopathol Pharmacol 16(1), 89
(2003): Naisbitt DJ+, J Allergy Clin Immunol 111(6), 1393
(2002): Beller TC+, Allergy Asthma Proc 23(6), 415
(2002): Monzon S+, Contact Dermatitis 47(6), 361
(2001): Hebert AA+, J Clin Psychiatry 62(suppl 14), 22
(2001): Lalanza J+, Aten Primaria 28(3), 213
(2000): Schaub N+, Allergy 55, 191
(1999): Borowitz SM, Pediatric Pharmacotherapy 5, 3
(1999): Brown TS+, Pediatr Dermatology 16, 46
(1999): Guberman AH+, Epilepsia 40, 985
(1999): Knowles SR+, Drug Safety 21, 489
(1999): Mylonakis E+, Ann Pharmacol 33, 557
(1999): Ronsdorf A+, Schweiz Rundsch Med Prax 88(41), 1660
(1998): Chapman MS+, Br J Dermatol 138, 710
(1998): Iannetti P+, Epilepsia 39, 502
(1998): Tugendhaft P+, JAmAcadDermatol38, 785 (phenytoinlike)
(1997): Jones D+, JAmAcadDermatol36, 1016 (phenytoin-like)
Myalgia/Myositis/Myopathy/Myotoxicity (>1%)
Porphyria
(1996): Gregersen H+, Ugeskr Laeger (Danish) 158, 4091
Pseudolymphoma
(1998): Pathak P+, Neurology 50, 1509
Rhabdomyolysis
(1997): Chattergoon DS+, Neurology 49(5), 1442 (with valproic
acid)
LANSOPRAZOLE
Trade name: Prevacid (TAP)
Indications: Active duodenal ulcer
Category: Proton pump inhibitor
Half-life: 2 hours
Clinically important, potentially hazardous interactions
with: eucalyptus, prednisone, sucralfate
Reactions
Skin
Acne (